从中选产品数量上看,最多的科伦集团,其次是倍特药业、石药集团、扬子江、华润医药、齐鲁、国药集团、复星医药、山东新华制药等。2025年1月1日,和黄医药发布公告,宣布达成两项协议以6.08亿美元(人民币44.78亿元)现金向上海金浦健服股权投资管理有限公司(简称“金浦健服投资管理”)和上海医药集团股份有限公司(简称“上海医药”)出售其在上海和黄药业有限公司(简称“上海和黄药业”)的45%的股权。上海...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.